Arrowhead Pharmaceuticals (ARWR) reported fiscal 2026 revenue of $450.8 million, down from $829.4 million in fiscal 2025 as lower collaboration and license revenue outweighed initial REDEMPLO sales. Net loss was $724.2 million, versus $1.6 million, including a $215.0 million expense for a priority review voucher purchased in September.
REDEMPLO generated $6.6 million in product revenue. In Phase 3 SHASTA-3 and SHASTA-4 studies for severe hypertriglyceridemia, plozasiran produced median triglyceride reductions of 79% and 81%, respectively, at Month 12; a prespecified pooled analysis also found significantly fewer acute pancreatitis events. Arrowhead submitted an sNDA and said a potential U.S. launch is planned for Q2 2027, pending regulatory filing, review and approval. After year-end, the FDA accepted the planned application into its STAR pilot program, whose accepted applications qualify for six-month priority review. Arrowhead withdrew its notice to use the PRV and continues to hold it.
At September 30, 2026, cash, cash equivalents and restricted cash were $62.7 million, and available-for-sale securities were $1.13 billion. Operating activities used $271.9 million in cash. Management expects current resources and its operating plan to fund operations through at least 12 months from the financial statements’ issuance.
Arrowhead Pharmaceuticals reported FY2026 revenue of $450.817 million for the year ended September 30, 2026, compared with $829.448 million in FY2025. Net loss attributable to Arrowhead was $724.206 million, versus $1.631 million. Total cash resources were $1,192.983 million as of September 30, 2026, compared with $919.366 million a year earlier.
REDEMPLO new-to-brand prescriptions grew 63% quarter over quarter; 950 cumulative prescriptions had been received by quarter-end, with 300 more received afterward. In Phase 3 SHASTA-3 and SHASTA-4, median triglyceride reductions from baseline were 79% and 81%, respectively, and the company reported a 78% reduction in all adjudicated acute pancreatitis event rates versus placebo. Arrowhead submitted an sNDA for plozasiran in severe hypertriglyceridemia and is preparing for a potential U.S. launch in the second quarter of 2027, pending regulatory filing, review, and approval.
Arrowhead established a new $400 million senior secured term loan at SOFR plus 5.50%, compared with the retired facility’s 15% annual rate. The new facility matures in November 2031; the refinancing included a $68 million discount on the retired facility’s contractual prepayment amount.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) was the subject of an amended ownership report in which reporting persons FMR LLC and Abigail P. Johnson each reported beneficial ownership of 9,307,350 shares, or 6.6% of the class. The report states that one or more other persons are known to have rights to dividends or sale proceeds from the common stock, while no other person's interest exceeds 5% of the class.
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, with a fully funded $400.0 million facility maturing November 2, 2031. At Arrowhead’s election, interest is three-month Term SOFR (subject to a 1.00% floor) plus 5.50%, or a base rate (subject to a 2.00% floor) plus 4.50%, payable quarterly in cash; the prior loans carried fixed 15.0% interest paid in kind.
Arrowhead used cash on hand to repay the prior facility for an aggregate payoff of approximately $404.4 million, including approximately $363.8 million of outstanding principal and other amounts. The lenders accepted the payoff in full satisfaction, including the MOIC payment, at approximately $68 million below the 2.0x MOIC amount otherwise due for repayment on or before August 7, 2028. The new facility has no scheduled amortization, removes required prepayments from net sales of products, royalties, milestones, licensing or partnering proceeds, and pipeline-asset monetizations, and lowers the minimum unrestricted-cash covenant from $150.0 million to $125.0 million; substantially all company assets secure the debt.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Adeoye Y. Olukotun reported a sale of 2,000 shares of common stock on 2026-08-18 in an open-market or private transaction at $86.96 per share. Following this transaction, he directly holds 31,600 shares, which the company notes include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael S. Perry reported a sale of 11,600 shares of common stock on 2026-08-18. The price reported is a weighted average of $87.30 per share, with individual trades between $87.20 and $87.44. Following this transaction, he directly holds 111,459 shares, which include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions. The filing indicates the Rule 10b5-1 trading plan checkbox was not marked.
Arrowhead Pharmaceuticals Inc. (ARWR) received a Rule 144 notice from director Adeoye Olukotun regarding a proposed sale of common stock. The filing states an intention to sell 2,000 shares of Arrowhead common stock through Merrill Lynch, with an aggregate market value of $173,876.47, on or about 08/18/2026 on NASDAQ. The company reports 141,254,467 shares outstanding. The 2,000 shares to be sold were acquired from the issuer as compensation on 12/18/2025.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael Perry has filed a notice of proposed sale of common stock under Rule 144. He plans to sell up to 11,600 shares of Arrowhead common stock through Merrill Lynch on NASDAQ, with an estimated aggregate market value of $1,012,171.97. The shares were acquired from the issuer as compensation on several dates in 2021, 2022, and 2025. Arrowhead had 141,254,467 shares outstanding of common stock; this is a baseline figure, not the amount being offered.
Arrowhead Pharmaceuticals, Inc. reported that investment firm Avoro Capital Advisors LLC and its controlling person Behzad Aghazadeh beneficially own 13,823,383 shares of Common Stock, including 2,467,828 shares issuable upon exercise of warrants. Based on 140,857,021 shares of Common Stock outstanding as of May 1, 2026, this represents 9.64% of Arrowhead’s outstanding Common Stock, assuming the warrants are exercised.
The reporting persons state they hold sole voting and sole dispositive power over all 13,823,383 shares, with no shared voting or dispositive power. The position is held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and the filers note that this report does not constitute an admission of beneficial ownership for legal purposes.
Arrowhead Pharmaceuticals reported fiscal 2026 third quarter results for the period ended June 30, 2026. Revenue was $75,253 thousand, up from $27,767 thousand a year earlier, while total operating expenses rose to $245,346 thousand, leading to a net loss attributable to Arrowhead of $194,280 thousand, or $(1.36) per diluted share.
Total cash resources, including cash and available-for-sale securities, were $1,566,886 thousand at June 30, 2026, against total liabilities of $1,645,972 thousand, including $682,707 thousand of convertible notes. REDEMPLO® commercial momentum continued, with prescription volume roughly doubling and new marketing authorizations in the EU and Australia.
Topline Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran in severe hypertriglyceridemia showed median triglyceride reductions of 79% and 81%, and a 78% reduction in acute pancreatitis events, including 100% reduction in a highest‑risk subgroup. Arrowhead acquired an FDA priority review voucher and signed a global license for ARO‑PNPLA3 with Madrigal, receiving a $25 million upfront payment and eligibility for up to $975 million in milestones.